Temocaprilat

• Description :

  Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE) . Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation[1][2][3][4].

• CAS Number :

  [110221-53-9]

• Product Name Alternative :

  Temocapril diacid; Temocaprilate; RS 5139

• UNSPSC :

  12352005

• Hazard Statement :

  H317, H319

• Target :

  Angiotensin-converting Enzyme (ACE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/temocaprilat.html

• Solubility :

  10 mM in DMSO

• Smiles :

  OC(CN1C[C@@H](C2=CC=CS2)SC[C@@H](C1=O)N[C@H](C(O)=O)CCC3=CC=CC=C3)=O

• Molecular Formula :

  C21H24N2O5S2

• Molecular Weight :

  448.56

• Precautions :

  H317, H319

• References & Citations :

  [1]Yasunari K, et al. Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation. J Cardiovasc Pharmacol. 2003 Dec;42 Suppl 1:S55-60. |[2]Püchler K, et al. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br J Clin Pharmacol. 1998 Oct;46 (4) :363-7. |[3]Ito N, et al. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am J Hypertens. 2007 Jul;20 (7) :792-9.|[4]Yang Z H, et al. P-540: Olmesartan and temocaprilat suppress IL-1 [beta]-induced IL-6 expression via a decrease in mRNA stability in vascular smooth muscle cells[J]. American Journal of Hypertension, 2002, 15 (S3) : 228A.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported